ORIC vs OSTX

Oric Pharmaceuticals, Inc. vs OS Therapies Incorporated — Valuation Comparison 2026

ORIC

Biotechnology
Oric Pharmaceuticals, Inc.
Quality
4.7
out of 10
Value Trap
18
SAFE
Price
$8.45
Last close
Models
7/13
Active
VS

OSTX

Biotechnology
OS Therapies Incorporated
Quality
3.1
out of 10
Value Trap
12
SAFE
Price
$1.98
Last close
Models
6/13
Active

Model-by-Model Comparison

ModelType ORIC Fair ValueORIC Upside OSTX Fair ValueOSTX Upside
Bayesian DCF Intrinsic $2.50 -70.4% $0.52 -74.0%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $3.62 -57.1% $0.04 -98.1%
PWERM Option-Based $8.17 -3.4% $2.10 +5.9%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for ORIC vs OSTX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ORIC vs OSTX — Which Stock Is More Undervalued?

ORIC scores higher with a 4.7/10 quality rating vs OSTX's 3.1/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Oric Pharmaceuticals, Inc. (ORIC) and OS Therapies Incorporated (OSTX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ORIC currently trades at $8.45 with a QOC of 4.7/10, while OSTX trades at $1.98 with a QOC of 3.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).